Posnoc (Positive Sentinel Node – A Randomised Trial of Adjuvant Therapy Alone Versus Adjuvant Therapy Plus Clearance or Axillary Radiotherapy)

Grant number: 1083172 | Funding period: 2015 - 2023

Completed

Abstract

POSNOC (POsitive Sentinel NOde – adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy) will address the key unresolved challenge in breast cancer surgery. A controversial US trial, ACOSOG Z0011, indicates that many breast cancer patients with limited disease in the sentinel node can safely avoid further nodal surgery. This would be a major advance, but there is widespread doubt that the results are broadly applicable. POSNOC will clarify this key issue.

Related publications (2)

POSNOC-POsitive Sentinel NOde: Adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes

A Goyal, GB Mann, L Fallowfield, L Duley, M Reed, D Dodwell, RE Coleman, A Fakis, R Newcombe, V Jenkins, D Whitham, M Childs, D Whynes, V Keeley, I Ellis, P Fairbrother, S Sadiq, K Monson, A Montgomery, W Tan

2021-12-02

Introduction ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes unde..

Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells

A Tachtsidis, LM McInnes, N Jacobsen, EW Thompson, CM Saunders

2016-08-01

Within the field of cancer research, focus on the study of minimal residual disease (MRD) in the context of carcinoma has grown ex..

University of Melbourne Researchers

Bruce Mann